Natixis Advisors L.P. grew its holdings in shares of Merit Medical Systems, Inc. (NASDAQ:MMSI – Free Report) by 9.5% during the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 43,671 shares of the medical instruments supplier’s stock after purchasing an additional 3,806 shares during the quarter. Natixis Advisors L.P. owned approximately 0.08% of Merit Medical Systems worth $3,229,000 at the end of the most recent quarter.
Several other hedge funds have also made changes to their positions in the business. Norges Bank purchased a new position in Merit Medical Systems during the fourth quarter worth about $37,702,000. Fuller & Thaler Asset Management Inc. boosted its position in shares of Merit Medical Systems by 68.7% in the fourth quarter. Fuller & Thaler Asset Management Inc. now owns 1,247,657 shares of the medical instruments supplier’s stock worth $88,110,000 after acquiring an additional 508,234 shares during the last quarter. Morgan Stanley grew its holdings in Merit Medical Systems by 108.7% in the fourth quarter. Morgan Stanley now owns 875,581 shares of the medical instruments supplier’s stock valued at $61,834,000 after purchasing an additional 456,031 shares during the period. Vanguard Group Inc. increased its position in Merit Medical Systems by 6.0% during the third quarter. Vanguard Group Inc. now owns 6,700,655 shares of the medical instruments supplier’s stock worth $378,653,000 after purchasing an additional 377,858 shares during the last quarter. Finally, Envestnet Asset Management Inc. raised its stake in Merit Medical Systems by 621.9% during the first quarter. Envestnet Asset Management Inc. now owns 397,116 shares of the medical instruments supplier’s stock worth $3,685,000 after purchasing an additional 342,104 shares during the period. Institutional investors and hedge funds own 93.16% of the company’s stock.
Merit Medical Systems Trading Up 0.0 %
Shares of MMSI opened at $65.30 on Friday. Merit Medical Systems, Inc. has a one year low of $52.79 and a one year high of $85.62. The stock has a 50-day moving average price of $75.08 and a 200 day moving average price of $76.39. The company has a debt-to-equity ratio of 0.28, a quick ratio of 1.52 and a current ratio of 3.13. The company has a market capitalization of $3.76 billion, a P/E ratio of 41.86, a P/E/G ratio of 1.99 and a beta of 0.96.
Insider Transactions at Merit Medical Systems
In other news, COO Neil Peterson sold 8,000 shares of the stock in a transaction dated Tuesday, August 22nd. The shares were sold at an average price of $67.91, for a total transaction of $543,280.00. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In other Merit Medical Systems news, Director A Scott Anderson sold 22,180 shares of the business’s stock in a transaction on Wednesday, August 9th. The shares were sold at an average price of $69.40, for a total transaction of $1,539,292.00. Following the completion of the sale, the director now owns 49,217 shares in the company, valued at $3,415,659.80. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, COO Neil Peterson sold 8,000 shares of the stock in a transaction on Tuesday, August 22nd. The stock was sold at an average price of $67.91, for a total transaction of $543,280.00. The disclosure for this sale can be found here. Insiders own 3.70% of the company’s stock.
Analyst Ratings Changes
A number of brokerages recently weighed in on MMSI. Raymond James lifted their target price on Merit Medical Systems from $88.00 to $93.00 in a report on Monday, May 8th. Canaccord Genuity Group reduced their price target on shares of Merit Medical Systems from $86.00 to $70.00 and set a “hold” rating on the stock in a research report on Monday, August 28th. Piper Sandler increased their price objective on shares of Merit Medical Systems from $85.00 to $92.00 and gave the stock an “overweight” rating in a research report on Friday, July 21st. Barrington Research restated an “outperform” rating and set a $95.00 target price on shares of Merit Medical Systems in a report on Wednesday, August 16th. Finally, StockNews.com downgraded Merit Medical Systems from a “buy” rating to a “hold” rating in a report on Monday, August 28th. Two equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. According to MarketBeat.com, Merit Medical Systems currently has a consensus rating of “Moderate Buy” and a consensus target price of $87.83.
Get Our Latest Report on Merit Medical Systems
Merit Medical Systems Profile
Merit Medical Systems, Inc designs, develops, manufactures, and markets single-use medical products for interventional, diagnostic, and therapeutic procedures, primarily in cardiology, radiology, oncology, critical care, and endoscopy. It operates in two segments, Cardiovascular and Endoscopy. The company provides peripheral intervention products for the diagnosis and treatment of diseases in peripheral vessels and organs; and cardiac intervention products, such as access, angiography, electrophysiology and cardiac rhythm management, fluid management, hemodynamic monitoring, hemostasis, and intervention to treat various heart conditions.
Featured Articles
- Five stocks we like better than Merit Medical Systems
- Stocks with Unusual Volume: How to Find Unusual Volume Stocks in Real Time
- 2 Stocks That Doubled EPS Estimates and Flashing Buy Signals
- How to Know Which Cryptocurrency to Buy: A Guide for Investors
- Toyota vs Tesla: The Tortoise And The Hare Race Has A New Meaning
- What Is WallStreetBets and What Stocks Are They Targeting?
- 5 Critical Takeaways From MongoDB’s Q2 Results for AI Investors
Receive News & Ratings for Merit Medical Systems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merit Medical Systems and related companies with MarketBeat.com's FREE daily email newsletter.
